Heron Therapeutics Inc Stock Price, News & Analysis

Heron Therapeutics (NASDAQ:HRTX) reported strong Q2 2025 financial results with total net revenue of $37.2 million, a 3.3% increase year-over-year. The company's Acute Care franchise showed impressive growth of 55.5% year-over-year in Q2 2025.

Key highlights include ZYNRELEF unit demand growth of 6.3% and APONVIE unit demand growth of 19% in Q2 compared to Q1 2025. The company completed a capital restructuring, reducing total debt from $175M to $145M and extending maturities to 2030.

Heron raised its 2025 Adjusted EBITDA guidance to $9.0-$13.0 million from $4.0-$12.0 million, while reaffirming net revenue guidance of $153-$163 million. The company ended Q2 with $40.6 million in cash and equivalents.

Heron Therapeutics (Nasdaq: HRTX) has rescheduled its second quarter 2025 financial results release and conference call to Friday, August 8, 2025, at 8:30 a.m. ET, moved up from the previously scheduled date of August 11, 2025.

The company will discuss Q2 2025 financial results and recent business highlights during the call. Participants are encouraged to dial in fifteen minutes before the start time using the provided registration link. The presentation will also be available via webcast on Heron's website, with a replay accessible for 60 days following the call.

Heron Therapeutics (NASDAQ: HRTX), a commercial-stage biotechnology company, has scheduled its second quarter 2025 financial results conference call for Monday, August 11, 2025, at 4:30 p.m. ET. The company will discuss Q2 2025 financial performance and recent business highlights during the call.

Participants can access the conference call through a registration link and are encouraged to dial in fifteen minutes before the scheduled start time. A webcast will be available through Heron's Investor Relations website section, with a 60-day replay period following the call.

Heron Therapeutics (NASDAQ: HRTX) reported strong Q1 2025 financial results with net revenue of $38.9 million, up 12.2% year-over-year, and record Adjusted EBITDA of $6.2 million. The growth was primarily driven by their acute care franchise, which increased 89.4%, with ZYNRELEF sales growing 60.4%. The company reached a settlement with Mylan regarding CINVANTI and APONVIE patent litigations, setting market entry for June 1, 2032. Heron raised its 2025 Adjusted EBITDA guidance to $4-12M from $0-8M, while maintaining net revenue guidance of $153-163M. The company's cash position stood at $50.7M as of March 31, 2025. Notable developments include the implementation of Non-Opioid Policy for Pain Relief and successful launch of the VAN for ZYNRELEF, with plans for a Prefilled Syringe launch in early 2027.

Heron Therapeutics (NASDAQ: HRTX) has reached a settlement agreement with Mylan Pharmaceuticals, a Viatris company, regarding patent litigation for CINVANTI® and APONVIE® injectable emulsions. The settlement grants Mylan a license to market generic versions of both drugs in the United States starting June 1, 2032, or earlier under certain circumstances.

The patent litigations were initiated by Heron in September 2023 and January 2024 after Mylan sought FDA approval for generic versions before the Heron Patents' expiration in 2035. Both companies will file for dismissal of the pending litigations with the U.S. District Court for the District of Delaware.

Heron Therapeutics has appointed Mark Hensley as Chief Operating Officer, bringing over fifteen years of pharmaceutical industry experience to the commercial-stage biotech company. Hensley previously served as CEO of Veloxis Pharmaceuticals from 2021 to 2024, and held COO and CCO positions from 2018 to 2021.

As part of his employment package, Hensley will receive significant inducement awards including:

• 500,000 shares stock option
• 500,000 restricted stock units
• Performance-based option for up to 900,000 shares

The compensation structure includes a 4-year vesting schedule for options and RSUs, with performance stock options tied to company stock price goals. CEO Craig Collard emphasized Hensley's role in driving operational efficiency and executing growth initiatives in Heron's next phase.

Heron Therapeutics (HRTX) has announced it will host a conference call and live webcast on Tuesday, May 6, 2025, at 8:00 a.m. ET to discuss its first quarter 2025 financial results and recent business highlights.

Participants are encouraged to dial in fifteen minutes before the scheduled start time to avoid delays. The event will be accessible via phone through a registration link and webcast through the Investor Relations section of Heron's website. A recording will be available on the company's website for 60 days following the call.

Heron Therapeutics (HRTX) reported strong financial results for Q4 and full-year 2024, achieving Q4 GAAP Net Income of $3.6 million and full-year net revenue of $144.2 million, marking a 14% year-over-year increase. The company delivered full-year 2024 adjusted EBITDA of $8.6 million.

Key highlights include ZYNRELEF Q4 2024 net revenue of $8.5 million and the launch of the ZYNRELEF Vial Access Needle (VAN) in December 2024. The company secured a favorable U.S. District Court ruling in a patent lawsuit against Fresenius Kabi USA, upholding CINVANTI patents through 2035.

ZYNRELEF's expanded label indications now cover an estimated 17 million annual targeted procedures. The product will continue receiving separate payment until at least end of 2027 under CMS policy. The newly launched VAN is expected to simplify preparation and reduce withdrawal time to 20-45 seconds.

Heron Therapeutics (HRTX) has announced it will host a conference call and live webcast on Thursday, February 27, 2025, at 8:00 a.m. ET to discuss its fourth quarter and full year 2024 financial results, along with recent business highlights. The company encourages participants to dial in fifteen minutes before the scheduled start time to avoid delays. The webcast will be available under the Investor Relations section of Heron's website, with an archive accessible for 60 days following the call.